Market Place
Sourcing Support
Kyverna`s Full SPS Data Sets Stage for First Autoimmune CAR-T Nod
21 Apr 2026 //
FIERCE BIOTECH
Kyverna Therapeutics Hosts Neuroimmunology Franchise Data Call
09 Apr 2026 //
GLOBENEWSWIRE
Kyverna Therapeutics Updates Business And Reports 2025 Financials
26 Mar 2026 //
GLOBENEWSWIRE
Kyverna Therapeutics To Unveil Neuroimmunology Franchise Data
05 Mar 2026 //
GLOBENEWSWIRE
Kyverna Therapeutics to Attend Upcoming March Investor Conference
03 Mar 2026 //
GLOBENEWSWIRE
Kyverna Updates Corporate Strategy At J.P. Morgan Conference
12 Jan 2026 //
GLOBENEWSWIRE
Kyverna Therapeutics at 2026 J.P. Morgan Healthcare Conference
05 Jan 2026 //
GLOBENEWSWIRE
Kyverna Therapeutics Prices $100M Public Stock Offering
17 Dec 2025 //
GLOBENEWSWIRE
Kyverna Therapeutics Reports Positive KYSA-8 Trial Results
15 Dec 2025 //
GLOBENEWSWIRE
Kyverna Therapeutics To Release KYV-101 Phase 2 Trial Results
14 Dec 2025 //
GLOBENEWSWIRE
Kyverna Therapeutics To Present at Jefferies Healthcare Conf
10 Nov 2025 //
GLOBENEWSWIRE
Kyverna CAR T Shows Efficacy in Myasthenia Gravis Ph 3 Prep
30 Oct 2025 //
BIOSPACE
Kyverna Links CAR-T to Autoimmune Improvements in Small Trial
29 Oct 2025 //
GLOBENEWSWIRE
Kyverna Therapeutics Hosts Conference On KYV-101 Phase 2 Data
22 Oct 2025 //
GLOBENEWSWIRE
Kyverna lays off 16% as autoimmune CAR-T plans take shape
14 May 2025 //
FIERCE BIOTECH
Kyverna Therapeutics Business Update & Reports Q3 Results
13 Nov 2024 //
PR NEWSWIRE
Kyverna Highlights KYV-101 Potential for Neuroinflammation
18 Sep 2024 //
PR NEWSWIRE
Kyverna`s KYV-101 Gets FDA IND Clearance For Stiff-Person Syndrome Trial
20 Jun 2024 //
PR NEWSWIRE
Kyverna To Attend AAN With KYV-101 Neuro Autoimmune Data
11 Apr 2024 //
PR NEWSWIRE
Kyverna Therapeutics Announces Closing of Initial Public Offering
12 Feb 2024 //
PR NEWSWIRE
Kyverna CEO: `We`re in the next phase of medicine`
09 Feb 2024 //
FIERCE BIOTECH
Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering
07 Feb 2024 //
PR NEWSWIRE
Kyverna seeks $182M IPO as biotech runs multiple autoimmune CAR-T trials
01 Feb 2024 //
ENDPTS
CAR-T developer Kyverna is latest clue biotech IPOs are back
17 Jan 2024 //
FIERCE BIOTECH
Autoimmune CAR-T biotech Kyverna is considering an IPO next month
12 Jan 2024 //
ENDPTS
Kyverna`s KYV-101 Receives Clearance for Treatment of Multiple Sclerosis
03 Jan 2024 //
PR NEWSWIRE
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101
13 Dec 2023 //
PR NEWSWIRE
Kyverna Therapeutics Announces Publication in The Lancet Neurology
15 Nov 2023 //
PR NEWSWIRE
Kyverna Announces Achievement of Phase 1 Trial of CD19 CAR T-Cell Therapy
13 Sep 2023 //
PR NEWSWIRE
GordonMD® Invests in Clinical Stage Cell Therapy Company Kyverna
15 Aug 2023 //
BUSINESSWIRE
